Spineology secures FDA approval for use of allograft bone with Rampart Interbody fusion devices

12 October 2016 (Last Updated October 12th, 2016 18:30)

US-based Spineology has received US Food and Drug Administration (FDA) approval to use allograft bone with its Rampart Interbody fusion devices.

US-based Spineology has received US Food and Drug Administration (FDA) approval to use allograft bone with its Rampart Interbody fusion devices.

The Rampart Interbody fusion devices incorporate large graft windows to help healing, and a recently enhanced instrumentation system.

Further, the devices are available sterile packed, thereby removing the requirement for continual reprocessing, which cuts down costs for customers.

"In addition to reducing patient morbidity and enhancing surgical efficiency we expect this approval will provide Spineology with an excellent platform for delivery of our new Incite Cortical Fibers."

Spineology chief executive officer John Booth said: “This approval and our recent partnership expansion with Musculoskeletal Transplant Foundation (MTF) provides us the ability to pair MTF allografts with the Rampart family of interbody devices.

In addition to reducing patient morbidity and enhancing surgical efficiency we expect this approval will provide Spineology with an excellent platform for delivery of our new Incite Cortical Fibers.”

Incite Cortical Fibers are a versatile bone grafting solution.

The fibers provide an osteoconductive and inductive matrix, handling properties, in-situ expansion and placement options through a variety of delivery methods.

Spineology offers anatomy conserving spinal technologies for surgeons and patients.